Related Experiment Video

Updated: May 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

Cuilan Li1, Vincent Ws Liu, Pui M Chiu

  • 1Department of Obstetrics and Gynecology, LKS Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.

BMC Cancer
|August 18, 2012
PubMed
Abstract

Insights

Aberrant expression of AMP-activated protein kinase (AMPK) subunits is common in ovarian cancer. Specific subunit levels correlate with tumor subtypes, stage, and patient prognosis, suggesting distinct roles in carcinogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • AMP-activated protein kinase (AMPK) is a potential cancer therapy target.
  • Expression of AMPK subunits in human cancers is underreported.
  • This study investigates AMPK subunit expression in ovarian carcinomas.

Purpose of the Study:

  • To determine the expression levels of AMPK subunits in ovarian carcinomas.
  • To correlate AMPK subunit expression with clinicopathological parameters.
  • To explore the potential role of AMPK in ovarian cancer development.

Main Methods:

  • Quantitative PCR (Q-PCR) and immunohistochemical staining (IHC) were used.
  • Expression of AMPK-α1, -α2, -β1, -β2, -γ1, and -γ2 subunits was analyzed.
  • Expression levels were compared between tumors and normal tissues and correlated with clinical data.

Main Results:

  • Most AMPK subunits (except AMPK-α1) were overexpressed in ovarian carcinomas.
  • Overexpression of AMPK-α2, -β1, and -β2 was confirmed by IHC.
  • Specific subunits correlated with tumor subtypes (e.g., AMPK-α2 with endometrioid), stage (e.g., AMPK-β1 with early stage), and better prognosis (AMPK-α2).

Conclusions:

  • Aberrant AMPK subunit expression is implicated in ovarian carcinogenesis.
  • Individual AMPK subunits may possess unique functions beyond the AMPK complex.
  • AMPK subunit expression patterns have distinct clinical implications in ovarian cancer.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...